ARVEE vs TRANSPEK: Stock Comparison
TRANSPEK is the larger company by market capitalisation. ARVEE LABORATORIES I shows a higher ROE, faster revenue growth and lower leverage, while TRANSPEK shows a lower P/E and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ARVEE leads 8; TRANSPEK leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ARVEE | TRANSPEK |
|---|---|---|
| Sector | Chemicals | — |
| Industry | Specialty Chemicals | — |
Price
| Metric | ARVEE | TRANSPEK |
|---|---|---|
| Live Price | ₹174.06 | ₹1,232.6 |
| Day Change | 1.15% | -2.36% |
| Volume | 791 | 5,657 |
| 52-Week High | ₹290.78 | ₹1,447.9 |
| 52-Week Low | ₹129.11 | ₹952.3 |
| Distance from 52W High | -40.14% | -14.87% |
Valuation
| Metric | ARVEE | TRANSPEK |
|---|---|---|
| Market Cap | ₹191 Cr | ₹760 Cr |
| P/E Ratio | 69.87x | 15.66x |
| P/B Ratio | 5.22x | 0.8x |
| EPS | ₹1.54 | ₹15.98 |
| Book Value | ₹30.66 | ₹1,373.97 |
| Dividend Yield | 0% | 1.47% |
Growth
| Metric | ARVEE | TRANSPEK |
|---|---|---|
| Revenue Growth (TTM YoY) | 67.5% | 0% |
| EPS Growth (TTM YoY) | 684.4% | 0% |
| Qtr Sales Growth | 59.43% | 0% |
| Qtr Profit Growth | 225.68% | 0% |
Profitability & Leverage
| Metric | ARVEE | TRANSPEK |
|---|---|---|
| ROE | 7.48% | 5.95% |
| ROCE | 7.73% | 6.87% |
| Net Margin | 7.65% | 7.35% |
| Operating Margin | 8.46% | 11.15% |
| Debt to Equity | 0.03x | 0.06x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ARVEE | TRANSPEK |
|---|---|---|
| Promoter Holding | 73.5% | 57.27% |
| FII Holding | 0% | 0.02% |
| DII Holding | 0% | 1.05%▼ 0.55 pp |
| Public Holding | 26.5% | 41.66%▲ 0.75 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ARVEE LABORATORIES I and TRANSPEK.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.